Form 4: Cocrystal Pharma Director Plans Significant Stock Purchase

Phillip Frost, a Director and 10% owner of Cocrystal Pharma, disclosed a planned acquisition of 50,000 common shares under a Rule 10b5-1 plan.

Summary

• Phillip Frost, M.D., a Director and 10% owner of Cocrystal Pharma, Inc. (COCP), reported a planned acquisition of common stock.
• The transaction involves the acquisition of 50,000 shares of common stock at a weighted average price of $0.9456 per share.
• The shares are planned to be purchased on February 6, 2026, under a Rule 10b5-1 pre-arranged trading plan.
• The purchase price ranged from $0.8899 to $0.9880 per share.
• Following this planned transaction, Frost Gamma Investments Trust, for which Dr. Frost is the trustee, will indirectly beneficially own 1,888,551 shares of common stock.
• Additionally, Dr. Frost directly beneficially owns 27,100 shares of common stock, which includes shares issuable upon vesting of restricted stock units.
• Dr. Frost disclaims beneficial ownership of securities held by Frost Gamma Investments Trust and OPKO Health, Inc., except to the extent of any pecuniary interest.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. Insider buying, particularly from a significant shareholder and director, generally reflects confidence in the company's future, though the transaction is planned for a future date.

Positives

• A Director and 10% owner planning to acquire additional shares signals confidence in the company's future prospects.
• The planned purchase of 50,000 shares represents a notable insider investment.

Future Outlook

The filing indicates a planned future transaction where a key insider intends to increase their stake in Cocrystal Pharma, Inc. on February 6, 2026, suggesting a positive outlook from management's perspective.

Management Comments

• Phillip Frost, M.D., as the reporting person, signed the statement of changes in beneficial ownership.

Industry Context

StockSavvy.ai notes that insider buying, especially from a director and significant owner, can often be interpreted by the market as a positive signal, indicating management's belief in the company's undervaluation or strong future prospects, which is a common trend observed in the biotechnology sector where R&D milestones can significantly impact stock performance.

Related Party Transactions

• The 1,888,551 shares are held indirectly by Frost Gamma Investments Trust, of which Phillip Frost M.D. is the trustee. The beneficial ownership structure involves Frost Gamma L.P., Frost Gamma, Inc., and Frost-Nevada Corporation, with Dr. Frost disclaiming beneficial ownership except for pecuniary interest.
• The filing explicitly states that it does not include securities owned directly by OPKO Health, Inc., a company where Dr. Frost is Chairman and CEO, and he disclaims beneficial ownership of those securities.

Stakeholder Impact

• Shareholders may view the planned insider purchase as a positive indicator of management's belief in the company's value, potentially boosting investor confidence.
• The transaction reinforces the alignment of interests between a significant owner/director and other shareholders.

Next Steps

• The planned acquisition of 50,000 common shares is scheduled to occur on February 6, 2026.

Key Dates

Recommendation

The planned purchase by a director and 10% owner, Phillip Frost, signals strong insider confidence in Cocrystal Pharma's future. Such insider buying is often a bullish indicator, suggesting that those with the most intimate knowledge of the company believe its stock is undervalued or poised for growth. This action, especially from a significant stakeholder, warrants a 'buy' recommendation for investors looking for positive insider sentiment.

Keywords

Cocrystal Pharma, COCP, Phillip Frost, Insider Buying, Form 4, Stock Purchase, 10b5-1 Plan, Biotechnology, Pharmaceuticals